| Pfizer Seeks EU Approval for Axitinib - Zacks.com |
|
|
Zacks.com Pfizer is seeking EU approval for the use of axitinib in treatment-failed patients with advanced renal cell carcinoma (RCC). The regulatory filing was based on phase III data from the AXIS 1032 trial. The AXIS 1032 trial, which was conducted in ... Pfizer asks EU to approve kidney cancer drug BusinessWeek Pfizer Files For European Regulatory Review Of Axitinib For Patients With |